Stage 4 cancer --  the treatment target of new very

New Post Public Reply Private Reply Replies (1) Message Board
bellsandwhistles bellsandwhistles #11952
Stage 4 cancer --  the treatment target of new very expensive Big Pharma drugs called "angiogenesis inhibitors" (idea being deprive blood to tumor) -- is the terminal stage of cancer progression when cancer cells spread throughout the body and multiply. Big Pharma's newly approved Zaltrap (Aug 2012) is a last resort drug intended for stage 4 colorectal cancer treatment after chemotherapy fails. Treatment with Zaltrap can be enormously expensive, as Dr. Saltz indicated. Like Avastin, Zaltrap is an "angiogenesis inhibitor" that uses the tact of choking off the blood supply to tumors. Even so, the median survival rate for patients using Zaltrap (in combination with their existing chemo) is  24 days. The PR announcing FDA approval and clinical trial results of Zaltrap clinical was hardly a celebration -- the average life extension being marginal and contraindications being very unpleasant or even fatal.

The premise of cutting off the blood to tumors is something like an army laying seige to an enemy city. The seige takes its toll on both sides of the conflict. On the other hand, the all-natural "cannabinoid complex" approach, as exemplified by high-dose Dharmanol, is to fight the enemy cancer by strengthening to a maximum the human body's own best defenses (immunity functions of the built-in endocannabinoid system) against the enemy cancer while doing no harm to the body itself.

Zaltrap v. Dharmanol? "Dang it all, give me some Dharmanol!"

Zaltrap
"The study was designed to measure overall survival, or the length of time a patient lived.  Patients who were assigned to receive the Zaltrap plus FOLFIRI combination lived an average of 13.5 months compared to an average of 12 months for those receiving FOLFIRI (chemo regimen) plus placebo. A reduction in tumor size occurred in 20 percent of patients receiving the Zaltrap plus FOLFIRI combination versus 11 percent for those receiving FOLFIRI plus placebo.

"In addition, the clinical trial demonstrated an improvement in progression-free survival, or the time a patient lived without the cancer progressing. The progression-free survival for patients receiving the Zaltrap plus FOLFIRI combination was 6.9 months compared with 4.7 months for those receiving FOLFIRI plus placebo.

"Zaltrap is being approved with a Boxed Warning alerting patients and health care professionals that the drug can cause severe and sometimes fatal bleeding, including gastrointestinal bleeding, and the development of holes in the gastrointestinal tract. Zaltrap can also make it more difficult for wounds to heal."

The most common side effects observed in patients receiving Zaltrap plus FOLFIRI were decreased white blood cell count, diarrhea, mouth ulcers, fatigue, high blood pressure, increased amount of protein in the urine, weight loss, decreased appetite, abdominal pain, and headache.



Stage 0 'in situ'

"A cell that becomes a cancer cell usually does so in the company of other similar cells. Often, but not always, it can produce a tumour right there in that tissue, in a way that poses little or no threat to life. This is called in situ cancer; that is, cancer in the position where it started. It is probable that some cancers never go beyond this early stage."
Stage 1: localised cancer

"At the next stage, the cancer cells gain the ability to pass through the 'basement membrane', that is the thin, fibrous boundary to the tissue in which the cancer began, and to invade neighbouring tissue. This invasion is a serious step, because it indicates that the growing cancer cells may threaten life.

"While the cancer remains a single lump, partly in the tissue where it began and partly in a neighbouring tissue, it is said to be in the localised stage."

Stages 2 and 3: regional spread

"Once a cancer cell has invaded, a common next step is for one of its daughter cells to invade through a lymph vessel (a vessel like a blood vessel that carries the clear fluid called lymph, which is all the time exuding into tissue from our blood capillaries (the smallest blood vessels), back to the blood stream).

"On the way to the blood stream, the cancer cell can get caught in a lymph node, one of the powerhouses of the body's immune system. There it might provoke an immune response against it, which can go on to destroy it and the other cancer cells. Wonderful!

"Sometimes, though, it divides and forms a lump in the lymph node. This stage is often referred to as regional spread. That is, the cancer has spread within the general region in which it first began but not to other parts of the body."

Stage 4: distant spread

"The next step can be quite varied. Cells from the lump in the lymph node may spread further through lymph vessels to more distant lymph nodes or on into the blood stream. Or cells from the original lump may invade a capillary and enter the blood stream that way.

"Either way, once in the blood stream, the cancer cells can go just about anywhere in the body, form new colonies and spread further. This is the stage of distant spread."

SK3 Group Inc. (SKTO) Stock Research Links

SKTO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Western Microsurgical Expands Through Strategic Acquisitions

Updated Category News Views 67

Western Microsurgical's Bold Moves Western Microsurgical (WMS) is out here making waves, pulling off some serious strategic plays with the acquisitions of Q Surgical and Proficient Surgical. Now, this ain't some fly-by-night decision—this is about securing territory and leveling up their game in surgical microscopes and operating room supplies. With a footprint that'll...

Continue Reading
U.S.-Saudi Business Leaders Eye Growth Amid Challenges

Updated Category News Views 107

Revitalizing a Strategic Partnership Monday's meeting of the U.S.-Saudi Business Council wasn't just another gathering of suits; it was about re-kindling the investment flame between these two economic giants. Chaired by powerhouses Lubna Olayan and Jane Fraser, this wasn't a mere photo op. It was a call to arms in a landscape riddled with hurdles but bursting with...

Continue Reading
DexCom Faces Scrutiny: Fiduciary Breach Questioned

Updated Category News Views 190

Is DexCom’s Leadership Under The Gun? Here's the scoop, folks—DexCom, Inc. (NASDAQ:DXCM) has been hit with some serious questions recently. Nothing like a potential fiduciary breach to shake things up. October 27, 2026, is when the news broke, with Halper Sadeh LLC taking the reins on this investigation. They’re poking around to see if DexCom’s top dogs stumbled...

Continue Reading
North Fork Mono Casino Opens: A $750 Million Bet

Updated Category News Views 57

A New Spin in Madera Cue the fanfare, folks! The North Fork Mono Casino just threw open its doors earlier than expected today, marking a hefty $750 million wager right in the heart of California's Central Valley. It's a big deal managed by Station Casinos, part of Red Rock Resorts, Inc. (NASDAQ: RRR)—teaming up with the North Fork Rancheria of Mono Indians for a...

Continue Reading
DICK'S Sporting Goods Faces Investor Lawsuit Deadline Looms

Updated Category News Views 23

A Rough Tumble for DICK'S Sporting Goods Let's cut to the chase: DICK'S Sporting Goods, Inc. (NYSE:DKS) just took a nosedive. We're talking a hard 30.68% fall on the stock, plummeting to $124.31 a share as of August 25, 2026. Now, if you were caught up in this whirlwind as an investor, you'd be forgiven for having a few choice words for the powers that be over at DICK'S....

Continue Reading
Noma Hits Fortune Cyber 60 with AI Security Success

Updated Category News Views 13

Celebrating an AI Security Standout Well, look at that, Noma's found itself on the Fortune Cyber 60 list for 2026-2027. This listing isn't just some vanity metric. We’re talking about getting the nod from heavyweights like Lightspeed Venture Partners and Amazon Web Services. It recognizes them among 60 pivotal, venture-backed cybersecurity players, and sure, it’s in...

Continue Reading
oToBrite Unveils Avant-Garde Robotics Vision Tech at ROBOTWORLD

Updated Category News Views 57

An Eye on the Future: oToBrite's Bold Vision for Robotics Strolling down the aisles at ROBOTWORLD 2026, there's a palpable energy buzzing around oToBrite's booth. These folks are showcasing vision technology that's not just about snapping slick photos—it's about reshaping how machines see the world. And, let me tell you, if there’s one place to flaunt cutting-edge...

Continue Reading
Bank Leumi Q3 Earnings Preview: Key Dates & Insights

Updated Category News Views 61

A Closer Look at Bank Leumi's Upcoming Q3 Release Take a seat, folks. Bank Leumi’s gearing up to spill the beans on their Third Quarter 2026 earnings come November 17th. If you’re in the financial world, you might want to mark your calendar because these reports tend to shake things up. You know how these go - numbers rolling out, market responses, and plenty of...

Continue Reading
Jiahui's Bold Leap into Global Cell Therapy Market

Updated Category News Views 66

Jiahui's International Cell Therapy Center: A New Era Jiahui International Hospital is shaking up the healthcare scene with its fresh International Cell Therapy Center, diving headfirst into the cutting-edge world of CAR-T treatments. It's not every day you see this kind of bold move, especially from a player aiming to extend their reach both in China and abroad. Let's...

Continue Reading
CELSET Unveils SOLTOX: Expanding in Global Markets

Updated Category News Views 19

New Contender in the Global Botulinum Toxin Arena Launching a fresh player onto the international stage, CELSET INC. from Seoul throws down with SOLTOX, their own botulinum toxin Type A brand. This ain't your run-of-the-mill roll-out; it's another notch for Korean biotech trying to snag a piece of global market action. A Look at SOLTOX's Technical Makeup We’re talking...

Continue Reading